Muscarinic acetylcholine receptor M3
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Muscarinic acetylcholine receptor M3 as ChEMBL target CHEMBL320, mapped to UniProt P08483. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Muscarinic acetylcholine receptor M3 matters
Muscarinic acetylcholine receptor M3 is reviewed as Muscarinic acetylcholine receptor M3 (UniProt P08483); the current evidence base includes 12 approved drugs, 436 compounds, and 183 assays, with lead potency reaching pChEMBL 10.7.
Muscarinic acetylcholine receptor M3 Sequence length is 589 aa.
Review this target as Muscarinic acetylcholine receptor M3, mapped to UniProt P08483. Sequence length is 589 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 12 approved drugs, 436 compounds, and 183 assays for this target. The dominant activity type is KI. CHEMBL3298595 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL3298595 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor M3 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P08483, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3298595
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL3298599
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL376897
|
10.3 | EC50 | Approved |
|
|
No preferred name
CHEMBL3298588
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL3298596
|
10.2 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TIOTROPIUM BROMIDE
CHEMBL3545181
|
2004 |
|
|
DARIFENACIN
CHEMBL1346
|
2004 |
|
|
SOLIFENACIN
CHEMBL1734
|
2004 |
|
|
TOLTERODINE
CHEMBL1382
|
1998 |
|
|
METHACHOLINE
CHEMBL978
|
1986 |
|
|
SCOPOLAMINE
CHEMBL569713
|
1979 |
|
|
OXYBUTYNIN
CHEMBL1231
|
1975 |
|
|
CARBACHOL
CHEMBL14
|
1972 |
|
|
ATROPINE
CHEMBL517712
|
1960 |
|
|
METHSCOPOLAMINE
CHEMBL376897
|
1953 |